Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 2/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27400053 | 1.00 | GPR119 (0.46) | GPR119JAK2JAK1NR1H2PDE10A | |
| SCHEMBL23701484 | 0.84 | CACNA1B (0.36) | ALDH1A1MAPT | |
| SCHEMBL27402318 | 0.82 | GPR119 (0.34) | GPR119 | |
| SCHEMBL27402350 | 0.82 | GPR119 (0.34) | GPR119 | |
| SCHEMBL23701406 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL23701408 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL23701446 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MAPT | |
| SCHEMBL23701447 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MAPT | |
| SCHEMBL20511076 | 0.77 | GPR119 (0.67) | GPR119NR1H2PDE10AALDH1A1LMNA | |
| SCHEMBL27399965 | 0.77 | GPR119 (0.67) | GPR119NR1H2PDE10AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | GPR119 2107/4885JAK2 510/4885JAK1 1019/4885 |
| US-20210238179-A1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES USEFUL AS LOX INHIBITORS | LOX, LOXL1, LOXL3 | GPR119 2107/4885JAK2 510/4885JAK1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.